27 Jun Initiating Monthly Buprenorphine Injection After Single Dose of Sublingual Buprenorphine

This study and abstract presentation evaluated opioid withdrawal symptoms, safety and tolerability of initiating SUBLOCADE 300 mg one hour after administering a single dose of 4 mg transmucosal (sublingual) buprenorphine (BUP-TM).

26 participants received BUP-TM, 24 follow by  SUBLOCADE injection, and 20 completed the study.

Participants were evaluated for opioid withdrawal symptoms as well as safety and tolerability of SUBLOCADE 300 mg.

The main findings from the study were:

• Two of the 24 participants experienced precipitated withdrawal. No participants had severe withdrawal
• No serious Treatment Emergent Adverse Events were observed, nor were any related to SUBLOCADE treatment
• After SUBLOCADE injection, withdrawal symptoms and opioid craving scores improved within 12hours and sustained for 4 weeks
• The authors concluded that initiating SUBLOCADE 300 mg following a single 4 mg dose of  transmucosal buprenorphine show a safety profile similar to that observed with SUBLOCADE induction per current labeling.

Citation:

Weist et. Al.  Initiating Monthly Buprenorphine Injection After Single Dose of Sublingual Buprenorphine. #W102. Presented at College on Problems of Drug Dependence (CPDD), June 23, 2021. 

Sponsored by Indivior 

[wysija_form id=”3″]

[last-modified]

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on June 27, 2021 by Marie Benz MD FAAD